Welcome to our dedicated page for Nanobiotix S.A. news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. stock.
Overview of Nanobiotix S.A.
Nanobiotix S.A. is a clinical-stage biotechnology company that is pioneering the application of advanced nanotechnology to enhance radiotherapy outcomes in cancer treatment. At its core, the company is dedicated to developing a novel, nanomedicine-based approach that magnifies the effects of radiotherapy by utilizing its proprietary NanoXray technology. This approach is designed to increase radiation absorption in tumor cells while minimizing exposure to healthy tissues, thereby potentially optimizing cancer treatments for a variety of solid tumors.
Core Technology and Product Platform
The centerpiece of Nanobiotix's innovative portfolio is its NanoXray platform. This technology employs engineered nanoparticles that, once activated by ionizing radiation, act as radiotherapy enhancers. The primary product candidate, NBTXR3, is currently undergoing extensive clinical evaluation. Its design is intended to integrate seamlessly with conventional radiotherapy schedules, providing a complementary boost in localized treatment efficacy. By doing so, Nanobiotix seeks to address one of the major limitations in standard radiotherapy: the challenge of delivering sufficient dosage to tumor tissues while protecting normal, healthy cells.
Clinical Applications and Cancer Types
Nanobiotix's approach to cancer treatment is aimed at a broad spectrum of oncology indications. The company’s research and clinical trials involve solid tumors such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma, among others. The diverse range of targeted indications underscores the flexibility of the NanoXray technology when used across multiple routes of administration. Each treatment protocol is underpinned by a rigorous clinical development program that seeks to build upon standard radiotherapy practices with an added layer of nanotechnology-driven innovation.
Research and Clinical Development
The operational focus of Nanobiotix S.A. is firmly rooted in clinical research and development. The company actively pursues rigorous clinical trials to evaluate the safety, feasibility, and potential efficacy of its NanoXray-based products. One notable aspect of its development strategy is the ability to complement existing radiotherapy regimens, thus not requiring a complete overhaul of standard practices. This compatibility is essential, as it allows the integration of new therapeutic methods with established treatment protocols, paving the way for broader adoption within the oncology community.
Integration with Conventional Radiotherapy
A key advantage of Nanobiotix's methodology is its inherent compatibility with existing radiotherapy systems. Rather than replacing conventional treatments, the NanoXray technology is designed to work in synergy with them, potentially leading to improved outcomes without necessitating additional radiation doses. This dual approach not only preserves the integrity of standard-of-care treatments but also introduces a targeted mechanism that could enhance the therapeutic index of radiotherapy. For patients, this translates into a treatment strategy that may offer increased precision and a better risk-benefit profile.
Position within the Biotechnology and Oncology Landscape
In the competitive arena of biotechnology, Nanobiotix distinguishes itself through a specialized focus on nanomedicine and its applications in radiotherapy. While the biotechnology sector is vast and varied, the company’s streamlined operational model concentrates on one operating segment – the development of nanotechnology-enhanced radiotherapy products. This clear focus allows for deep specialization and a concentrated research effort, aspects that are critical in a field characterized by both high innovation potential and significant developmental challenges.
Clinical-Stage Development and Research Collaboration
Nanobiotix demonstrates a commitment to enhancing translational research by engaging in collaborative clinical trials across multiple geographies. Its clinical development pipeline not only evaluates the direct applications of NanoXray technology but also explores its possible integration into combination therapies, such as the burgeoning field of immuno-oncology. The company’s recent undertakings include preclinical research programs aimed at harnessing the potential of nanotechnology in stimulating immune responses against cancer. The strategic partnerships, including collaborations with international clinical centers and regional partners, provide a robust framework for evaluating the efficacy and safety of its treatments in diverse patient populations.
Innovation and Technological Differentiation
Nanobiotix’s use of advanced nanotechnology distinguishes it from many traditional oncology companies. The innovative concept of enhancing the physical properties of radiotherapy through nanomaterials reflects a significant paradigm shift in treatment methodology. By focusing on the cellular-level enhancement of radiation absorption, the company is addressing one of the key challenges in oncology: delivering effective doses to malignant cells while limiting collateral damage to surrounding tissue. This technological differentiation, rooted in rigorous scientific research and clinical validation, underscores the company’s authority in the field of nanomedicine.
Market Position and Value Proposition
Despite operating in a highly competitive and rapidly evolving biotechnology landscape, Nanobiotix S.A. has carved out a niche for itself by centering its value proposition on technological innovation and clinical utility. The integration of NanoXray technology with customary radiotherapy methods provides a unique solution for oncologists confronting the limitations of standard treatment protocols. Moreover, by enhancing the therapeutic ratio of radiotherapy, the company is positioning itself as a potential catalyst for improving patient outcomes across a range of cancer types. The clinical-stage focus of the business model emphasizes robust, evidence-based progress through stringent clinical evaluations.
Expertise, Experience, and Trustworthiness
The extensive scientific and clinical research undertaken by Nanobiotix is founded on years of accumulated expertise in both nanotechnology and oncology. The company’s management and research teams leverage deep industry knowledge to drive forward a pipeline of innovative therapeutic candidates. Detailed preclinical studies and ongoing clinical research protocols solidify its position as an expert in the field. By transparently releasing and discussing clinical trial data within the boundaries of established regulatory frameworks, Nanobiotix builds trust and a reputation for rigorous scientific inquiry and responsible innovation.
Summary
In summary, Nanobiotix S.A. is a clinical-stage biotechnology firm focused on pioneering nanomedicine applications to enhance the efficacy and safety of radiotherapy in cancer treatment. Through its innovative NanoXray platform and the development of its flagship product candidate NBTXR3, the company leverages targeted nanotechnology to potentially revolutionize treatment paradigms across a diverse range of solid tumors. Its focused clinical development strategy, integration with conventional radiotherapy, and steadfast commitment to scientific excellence collectively position Nanobiotix as a compelling subject of inquiry and analysis within the beleaguered but high-potential arena of oncology advancements.
Nanobiotix announced upcoming presentations of data from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) at the 2025 European Lung Cancer Conference (ELCC). The first study, presented by Dr. Saumil Gandhi, focuses on safety and early efficacy signals, including updated local PFS, for re-irradiation with JNJ-1900 in patients with unresectable, locoregional recurrent NSCLC.
The second study, presented by Dr. Colette Shen, evaluates safety and injection feasibility of JNJ-1900 in combination with nivolumab or pembrolizumab for treating patients with lung metastases from NSCLC or other solid tumors. Both presentations are scheduled for March 28th, 2025, at 8:00 AM EDT / 1:00 PM CET.
Nanobiotix (NASDAQ: NBTX) has amended its global licensing agreement with Johnson & Johnson's Janssen Pharmaceutica NV, strengthening its financial position through 2026. Key changes include:
- J&J will now cover most costs for the ongoing NANORAY-312 Phase 3 trial
- Overall deal value adjusted from $2.7B to $2.6B
- Potential milestone payments include:
- $1.77B for first programs including head and neck cancer and lung cancer
- $650M for five new potential indications
- $165M for Asian market developments
- $220M per new indication developed by Nanobiotix
The company maintains tiered double-digit royalties (low 10s to low 20s) and extends cash runway to mid-2026. Nanobiotix expects reduced operational cash burn and is exploring additional non-dilutive financing options to extend runway into 2027.
Nanobiotix (NBTX) has issued a standard regulatory filing regarding its voting rights and share capital in compliance with French regulatory requirements. The announcement was made in accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the French Financial Markets Authority regulations.
The company's shares are listed on both Euronext Paris (Compartment B) and Nasdaq under the ticker symbol NBTX. The company's ISIN code is FR0011341205.
Nanobiotix (NBTX) has released its latest voting rights and shares capital update as of January 31, 2025. The company reported 47,426,851 shares outstanding, with 49,208,659 theoretical voting rights and 49,186,541 exercisable voting rights.
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France, dual-listed on Euronext Paris and Nasdaq Global Select Market. The company specializes in physics-based therapeutic approaches and owns more than 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, has announced its participation in two major investor conferences in early 2025.
The company will participate in fireside chats at the following events:
- Guggenheim SMID Cap Biotech Conference on February 6, 2025, at 1pm ET in New York, featuring CFO Bart van Rhijn
- Leerink Global Healthcare Conference on March 12, 2025, at 10:40pm ET in Miami, featuring CEO Laurent Levy and CFO Bart van Rhijn
Both fireside chats will be webcast live through the company's website's Investors section, with replays available after the events.
Nanobiotix announced the dosing of the first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating JNJ-1900 (NBTXR3) for treating Stage 3 unresectable non-small cell lung cancer. The study will assess patients receiving standard chemoradiation followed by consolidation durvalumab.
The trial (NCT06667908) is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, under a global license agreement. JNJ-1900 is a potential first-in-class radioenhancer designed to address unmet needs in radiotherapy patients. This development follows the NANORAY-312 trial path for potential registration in head and neck cancer.
Nanobiotix (NBTX) has released its latest voting rights and shares capital statement as of December 31, 2024. The company reports 47,426,851 shares outstanding, with 49,204,910 theoretical voting rights and 49,182,792 exercisable voting rights.
Nanobiotix is a late-stage clinical biotechnology company listed on both Euronext Paris and Nasdaq Global Select Market. The company focuses on physics-based therapeutic approaches and owns more than 25 patent families across three nanotechnology platforms: oncology, bioavailability and biodistribution, and disorders of the central nervous system.
Nanobiotix (NBTX) announced a virtual event titled 'Accelerating the Future of Nanotherapeutics' scheduled for December 19, 2024, at 9:00 AM ET / 3:00 PM CET. The event will showcase the company's Curadigm Nanoprimer Platform, a new nanotherapeutic technology designed to enhance intravenously-administered therapeutics.
The presentation will feature CEO Laurent Lévy and Curadigm Head Matthieu Germain, followed by a panel discussion with experts including Margaret A. Liu, a globally recognized authority in gene therapy, vaccines, and immunotherapy. The company confirms its lead program is proceeding as planned while exploring new nanotherapeutic technologies to improve patient treatment outcomes.
Nanobiotix (NBTX) has reported its latest voting rights and share capital status as of November 30, 2024. The company has 47,426,851 shares outstanding, with 49,202,229 theoretical voting rights and 49,180,111 exercisable voting rights. Nanobiotix, founded in 2003 and headquartered in Paris, is a late-stage clinical biotechnology company listed on both Euronext Paris and Nasdaq Global Select Market. The company owns over 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.
Nanobiotix announced completion of Phase 1 study evaluating RT-activated NBTXR3 in pancreatic cancer patients. The study showed encouraging results with 23 months median Overall Survival from diagnosis in 22 patients with locally advanced or borderline resectable pancreatic cancer, compared to 19.2 months historical control at MD Anderson.
The treatment was well-tolerated, and investigators concluded the favorable safety profile and oncologic outcomes warrant further evaluation in a randomized trial. The FDA approved a protocol amendment to launch a new cohort studying NBTXR3 combined with standard-of-care concurrent chemotherapy, with recruitment currently ongoing. Full data presentation is expected at a medical congress in first half of 2025.
FAQ
What is the current stock price of Nanobiotix S.A. (NBTX)?
What is the market cap of Nanobiotix S.A. (NBTX)?
What is the core focus of Nanobiotix S.A.?
How does the NanoXray technology work?
Which cancer types are targeted by Nanobiotix's products?
What is NBTXR3?
How does Nanobiotix integrate its technology with traditional treatments?
What stage of development is Nanobiotix currently in?
What differentiates Nanobiotix in the oncology market?
